A Patient Registry of Patients With High-risk Neuroblastoma Being Treated With the Monoclonal Antibody Dinutuximab Beta
This study is a registry for children and teenagers with a type of cancer called neuroblastoma who are being treated with a medicine called dinutuximab beta. It's not a trial where doctors try out new treatments, but rather observes what happens in real life after the medicine has already been approved for use. The main goal is to collect information about how safe and effective dinutuximab beta is over time. Researchers will be looking at things like how long patients live, how much pain they experience, and if they have any side effects like nerve problems, vision changes, or heart issues. This helps to build a clearer picture of the medicine's long-term impact for patients in the UK and other countries.
Överblick
Vad handlar denna studie om?
Neuroblastoma is a type of cancer that usually affects young children. It's the most common solid cancer that starts outside the brain in children, and many are diagnosed before they turn five. Often, when it's found, the cancer has already spread or is considered high-risk. Despite new and better treatments, including strong chemotherapy, the outlook for these children can still be challenging.
Dinutuximab beta is a special antibody medicine. Think of antibodies as tiny scouts in your body that can identify and fight off certain unwanted cells. In this case, dinutuximab beta is designed to find and attach to neuroblastoma cancer cells. Once it attaches, it helps your body's immune system destroy these cancer cells. This medicine has already been studied in clinical trials and is approved for use.
This particular study isn't a new experiment with dinutuximab beta. Instead, it's a 'registry,' which means it collects information from many different patients who are already receiving the medicine as part of their standard care. It's like keeping a detailed diary for many patients to understand how the medicine works in the real world, outside of a strictly controlled trial. Researchers want to learn more about its long-term effects, including survival rates, how it affects pain, and if there are any specific side effects over time. This helps doctors and patients make informed decisions about treatment.
Viktiga punkter
- This study helps understand standard treatment for neuroblastoma in children and teenagers.
- It's a registry, not a trial testing a new medicine.
- Information is collected on how safe and effective dinutuximab beta is over the long term.
- Participation involves sharing medical information from your regular appointments.
- You won't receive extra tests or treatments by joining.
- Your information helps improve care for future patients.
Vem kan vara berättigad?
This study is for children and teenagers aged between 1 and 18 years old.
You might be able to take part if you have a high-risk form of neuroblastoma and are starting treatment with dinutuximab beta. This could be the standard version of the medicine that your doctor would prescribe, or if you're taking part in a different clinical trial where the dinutuximab beta is given according to standard approved practices.
To join, you (or your parent/guardian) must agree to be part of the registry and be willing to have your health information followed for up to 10 years. You wouldn't be able to join if you're receiving dinutuximab beta in another clinical trial where the medicine is being used in a way that isn't approved for general use in your country, or if you're not happy to have your information tracked for that length of time.
Kan denna studie passa dig?
Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.
- Are you between 1 and 18 years old?
- Do you have high-risk neuroblastoma?
- Are you starting treatment with dinutuximab beta (the standard, approved medicine)?
- Are you willing to have your health followed for up to 10 years?
- Are you happy for your medical information to be used for research?
Vad innebär deltagande?
If you take part in this study, you won't be given any new or experimental treatments. You'll simply be receiving dinutuximab beta as part of your regular care for neuroblastoma. The study team will then collect information about your health over time, without influencing your treatment choices. This will involve gathering details about your medical history, how you respond to the medicine, any side effects you might experience, and your general well-being. This information will be collected from your medical records during your regular hospital visits. The study plans to follow participants for up to 10 years to understand the long-term effects of dinutuximab beta.
Potentiella risker och fördelar
Platser (13)
- St. Anna KinderkrebsforschungVerifierat postnummerWien, Österrike
- Centre Oscar LambretVerifierat postnummerLille, Frankrike
- Hôpital de la Timone, Hôpital des EnfantsVerifierat postnummerMarseille, Frankrike
- Institut Gustave RoussyVerifierat postnummerVillejuif, Frankrike
- Charité BerlinVerifierat postnummerBerlin, Tyskland
- Universitätsmedizin GreifswaldVerifierat postnummerGreifswald, Germany
- IRCCS Istituto Giannina GasliniVerifierat postnummerGenova, Italy
- Uniwersytecki Szpital DziecięcyVerifierat postnummerKrakow, Polen
- Vall d'Hebron University HospitalVerifierat postnummerBarcelona, Spanien
- Hospital Universitario y Politecnico La Fe Avenida Fernando Abril MartorellVerifierat postnummerValencia, Spanien
- The Newcastle upon Tyne Hospitals NHS Foundation TrustVerifierat postnummerNewcastle upon Tyne, Storbritannien
- Birmingham BarnsjukhusVerifierat postnummerBirmingham, Storbritannien
Vanliga frågor
Vad är neuroblastom?
Neuroblastoma is a type of cancer that usually affects very young children and often starts in nerve tissue outside of the brain.
What is dinutuximab beta?
It's a special antibody medicine that helps your body's immune system find and destroy neuroblastoma cancer cells.
Is this a new treatment trial?
No, this is a 'registry' where doctors collect information on patients already receiving dinutuximab beta as part of their regular care. It's not testing a new treatment.
How long will I be followed?
The study plans to follow your health information for up to 10 years to understand the long-term effects of the medicine.
Kommer min behandling att förändras om jag går med?
No, joining this study will not change your medical treatment. You will continue to receive the care your doctor recommends.
Hur du får reda på mer
Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.
Diskussion
Gemenskapsdiskussion
Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.